Abstract
Typhoid fever continues to be a major public health concern, particularly in many low- and middle-income countries. The current threats of increasing antimicrobial resistance, urbanization, and climate change elevate the urgency for better prevention and control efforts for typhoid fever. In 2017, the results of ground-breaking research on typhoid conjugate vaccines (TCVs), the World Health Organization prequalification of a TCV, and global policy and financing decisions have set the stage for the introduction of TCVs into routine immunization programs in endemic countries. Country-level decision-making and program planning are critical for local uptake and sustainability.
Highlights
Introduction of Typhoid Conjugate Vaccines inAfrica and AsiaKathleen M
Prior to 2017, 2 typhoid vaccines were available: the oral, live attenuated Ty21a vaccine licensed for children aged ≥6 years, and an injectable Vi capsular polysaccharide vaccine licensed for children aged ≥2 years [4]
It has been difficult to incorporate these vaccines into routine immunization programs in low-resource countries because neither is approved for children aged
Summary
Typhoid fever continues to be a major public health concern, in many low- and middle-income countries. In 2017, the results of ground-breaking research on typhoid conjugate vaccines (TCVs), the World Health Organization prequalification of a TCV, and global policy and financing decisions have set the stage for the introduction of TCVs into routine immunization programs in endemic countries. TyVAC uses a multidisciplinary, iterative approach to accelerate the introduction of typhoid conjugate vaccines (TCVs) into low- and middle-resource countries, those eligible for support from Gavi, the Vaccine Alliance. Prior to 2017, 2 typhoid vaccines were available: the oral, live attenuated Ty21a vaccine licensed for children aged ≥6 years, and an injectable Vi capsular polysaccharide vaccine licensed for children aged ≥2 years [4] It has been difficult to incorporate these vaccines into routine immunization programs in low-resource countries because neither is approved for children aged
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
